{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:57:21Z","timestamp":1793505441200,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270153"],"award-info":[{"award-number":["82270153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270195"],"award-info":[{"award-number":["82270195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science Foundation of Peking University Cancer Hospital","award":["JC202403"],"award-info":[{"award-number":["JC202403"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hematologic malignancies are one of the most common types of cancer. This study aims to assess the global burden of hematologic malignancies and analyze the global epidemiological trends.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Through the Global Burden of Disease Study 2021 (GBD 2021) and the Global Cancer Observatory (GLOBOCAN) 2022 project, we comprehensively evaluated the global prevalence, incidence, mortality, and disability-adjusted life-years (DALYs) of seven major hematologic malignancies, as well as their respective age-standardized rates (ASR) per 100,000 population. Regions were classified using the Socio-demographic Index (SDI) to evaluate the correlation between disease burden and economic level. In addition, we analyzed disease-related risk factors and predicted future trends up to 2040.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>From 1990 to 2021\/2022, the number of global hematologic malignancy cases showed a continuously increasing trend, especially for non-Hodgkin lymphoma. However, the age-standardized death rates (ASDR) and age-standardized DALY rates (ASDALYR) of all types of hematologic malignancies tended to be stable or decline. For acute lymphoblastic leukemia, the number of death cases, ASDR, and ASDALYR decreased significantly. Nevertheless, the trends of hematologic malignancies varied by gender, age, and SDI. The burden of hematologic malignancies was generally higher in the elderly and male populations. Of course, acute lymphoblastic leukemia also imposed a huge burden on children, Hodgkin lymphoma also significantly burdened young people. Moreover, regions with a higher SDI had a higher incidence rate. Deaths related to smoking and high body mass index still played an important role in various regions, especially in regions with a higher SDI. It is predicted that the global age-standardized incidence rates (ASIR) and ASDALYR will show a slow downward trend by 2040.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Hematologic malignancies have remained a major global public health issue, with significant demographic and regional differences. The results of this study will provide a basis for analyzing the trends of the global disease burden of specific hematologic malignancies and offer a reference for health policymakers.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40164-025-00684-x","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:29:08Z","timestamp":1752776948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021"],"prefix":"10.1186","volume":"14","author":[{"given":"Tao","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"1","key":"684_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-024-01640-8","volume":"17","author":"Z Wu","year":"2024","unstructured":"Wu Z, Xia F, Lin R. Global burden of cancer and associated risk factors in 204 countries and territories, 1980\u20132021: a systematic analysis for the GBD 2021. J Hematol Oncol. 2024;17(1):119.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"684_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","volume":"13","author":"N Zhang","year":"2023","unstructured":"Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13(1):82.","journal-title":"Blood Cancer J"},{"issue":"4","key":"684_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","volume":"130","author":"J Taylor","year":"2017","unstructured":"Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017;130(4):410\u201323.","journal-title":"Blood"},{"issue":"1","key":"684_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","volume":"6","author":"JM Connors","year":"2020","unstructured":"Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner H-H, et al. Hodgkin lymphoma. Nat Rev Dis Primers. 2020;6(1):61.","journal-title":"Nat Rev Dis Primers"},{"issue":"9844","key":"684_CR5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848\u201357.","journal-title":"Lancet"},{"issue":"10230","key":"684_CR6","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146\u201362.","journal-title":"Lancet"},{"key":"684_CR7","doi-asserted-by":"crossref","unstructured":"Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026.","DOI":"10.1136\/bmj.n2026"},{"issue":"10129","key":"684_CR8","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524\u201337.","journal-title":"Lancet"},{"issue":"10314","key":"684_CR9","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","volume":"398","author":"J Cortes","year":"2021","unstructured":"Cortes J, Pavlovsky C, Sau\u00dfele S. Chronic myeloid leukaemia. Lancet. 2021;398(10314):1914\u201326.","journal-title":"Lancet"},{"issue":"10272","key":"684_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"3","key":"684_CR11","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"684_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-020-00908-z","volume":"13","author":"M Yi","year":"2020","unstructured":"Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1):72.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"684_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40364-024-00649-y","volume":"12","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Huang G, Cai X, Liu Y, Qian B, Li D. Global, regional, and National burden of acute myeloid leukemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Biomark Res. 2024;12(1):101.","journal-title":"Biomark Res"},{"key":"684_CR14","doi-asserted-by":"publisher","first-page":"1527198","DOI":"10.3389\/fpubh.2025.1527198","volume":"13","author":"L Zhuge","year":"2025","unstructured":"Zhuge L, Lin X, Fan Z, Jia M, Lin C, Zhu M, et al. Global, regional and National epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the global burden of disease study 2021. Front Public Health. 2025;13:1527198.","journal-title":"Front Public Health"},{"issue":"10440","key":"684_CR15","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/S0140-6736(24)00769-4","volume":"403","author":"CJL Murray","year":"2024","unstructured":"Murray CJL. Findings from the global burden of disease study 2021. Lancet. 2024;403(10440):2259\u201362.","journal-title":"Lancet"},{"issue":"10440","key":"684_CR16","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"Global burden of","year":"2024","unstructured":"Global burden of. 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2100\u201332.","journal-title":"Lancet"},{"issue":"10440","key":"684_CR17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"Global incidence","year":"2024","unstructured":"Global incidence. prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2133\u201361.","journal-title":"Lancet"},{"issue":"1","key":"684_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-025-01660-y","volume":"18","author":"T Li","year":"2025","unstructured":"Li T, Zhang H, Lian M, He Q, Lv M, Zhai L, et al. Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021. J Hematol Oncol. 2025;18(1):5.","journal-title":"J Hematol Oncol"},{"issue":"10440","key":"684_CR19","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"Global burden and strength of evidence for","year":"2024","unstructured":"Global burden and strength of evidence for. 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024;403(10440):2162\u2013203.","journal-title":"Lancet"},{"issue":"4","key":"684_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.2047-6310.2012.00064.x","volume":"7","author":"TJ Cole","year":"2012","unstructured":"Cole TJ, Lobstein T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes. 2012;7(4):284\u201394.","journal-title":"Pediatr Obes"},{"issue":"10","key":"684_CR21","doi-asserted-by":"publisher","first-page":"111045","DOI":"10.1016\/j.isci.2024.111045","volume":"27","author":"T Lan","year":"2024","unstructured":"Lan T, Lu Y, He J, Zhan C, Wang X, Shao X, et al. Global, reginal, National burden and risk factors in female breast cancer from 1990 to 2021. iScience. 2024;27(10):111045.","journal-title":"iScience"},{"issue":"10310","key":"684_CR22","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","volume":"398","author":"P Brice","year":"2021","unstructured":"Brice P, de Kerviler E, Friedberg JW. Classical hodgkin lymphoma. Lancet. 2021;398(10310):1518\u201327.","journal-title":"Lancet"},{"issue":"15","key":"684_CR23","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","volume":"391","author":"AF Herrera","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, et al. Nivolumab\u2009+\u2009AVD in Advanced-Stage classic hodgkin\u2019s lymphoma. N Engl J Med. 2024;391(15):1379\u201389.","journal-title":"N Engl J Med"},{"key":"684_CR24","doi-asserted-by":"publisher","first-page":"k3204","DOI":"10.1136\/bmj.k3204","volume":"362","author":"A Bowzyk Al-Naeeb","year":"2018","unstructured":"Bowzyk Al-Naeeb A, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ. 2018;362:k3204.","journal-title":"BMJ"},{"issue":"9","key":"684_CR25","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-Cell lymphoma. N Engl J Med. 2021;384(9):842\u201358.","journal-title":"N Engl J Med"},{"issue":"7721","key":"684_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-018-0457-8","volume":"561","author":"L Partridge","year":"2018","unstructured":"Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. Nature. 2018;561(7721):45\u201356.","journal-title":"Nature"},{"issue":"1","key":"684_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):29.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"684_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-017-0543-7","volume":"11","author":"X Yang","year":"2018","unstructured":"Yang X, Wang J. Precision therapy for acute myeloid leukemia. J Hematol Oncol. 2018;11(1):3.","journal-title":"J Hematol Oncol"},{"key":"684_CR29","doi-asserted-by":"publisher","first-page":"103607","DOI":"10.1016\/j.critrevonc.2022.103607","volume":"171","author":"SA Strickland","year":"2022","unstructured":"Strickland SA, Vey N. Diagnosis and treatment of therapy-related acute myeloid leukemia. Crit Rev Oncol Hematol. 2022;171:103607.","journal-title":"Crit Rev Oncol Hematol"},{"key":"684_CR30","doi-asserted-by":"crossref","unstructured":"Kotsiafti A, Giannakas K, Christoforou P, Liapis K. Progress toward better treatment of therapy-related AML. Cancers (Basel). 2023;15(6).","DOI":"10.3390\/cancers15061658"},{"issue":"1","key":"684_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","volume":"13","author":"B Samra","year":"2020","unstructured":"Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13(1):70.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"684_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","volume":"29","author":"A Rafae","year":"2024","unstructured":"Rafae A, van Rhee F, Al Hadidi S. Perspectives on the treatment of multiple myeloma. Oncologist. 2024;29(3):200\u201312.","journal-title":"Oncologist"},{"issue":"12","key":"684_CR33","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1182\/blood.2021012328","volume":"139","author":"S Buchmann","year":"2022","unstructured":"Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M, et al. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno consortium. Blood. 2022;139(12):1785\u201393.","journal-title":"Blood"},{"issue":"2","key":"684_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.seminhematol.2019.02.002","volume":"56","author":"TW LeBlanc","year":"2019","unstructured":"LeBlanc TW, Erba HP. Shifting paradigms in the treatment of older adults with AML. Semin Hematol. 2019;56(2):110\u20137.","journal-title":"Semin Hematol"},{"issue":"10","key":"684_CR35","doi-asserted-by":"publisher","first-page":"e729","DOI":"10.1016\/S2468-2667(24)00166-X","volume":"9","author":"Forecasting the effects of smoking prevalence scenarios on years of life lost","year":"2024","unstructured":"Forecasting the effects of smoking prevalence scenarios on years of life lost. And life expectancy from 2022 to 2050: a systematic analysis for the global burden of disease study 2021. Lancet Public Health. 2024;9(10):e729\u201344.","journal-title":"Lancet Public Health"},{"issue":"27","key":"684_CR36","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"10438","key":"684_CR37","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","volume":"403","author":"E Silkenstedt","year":"2024","unstructured":"Silkenstedt E, Salles G, Campo E, Dreyling M. B-cell non-Hodgkin lymphomas. Lancet. 2024;403(10438):1791\u2013807.","journal-title":"Lancet"},{"issue":"2","key":"684_CR38","doi-asserted-by":"publisher","first-page":"e2355727","DOI":"10.1001\/jamanetworkopen.2023.55727","volume":"7","author":"SK Hashmi","year":"2024","unstructured":"Hashmi SK, Bodea J, Patni T, Angel S, Bhakta NH, Jeha S, et al. COVID-19 in pediatric patients with acute lymphoblastic leukemia or lymphoma. JAMA Netw Open. 2024;7(2):e2355727.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"684_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-024-01623-9","volume":"17","author":"W Li","year":"2024","unstructured":"Li W, Liang H, Wang W, Liu J, Liu X, Lao S, et al. Global cancer statistics for adolescents and young adults: population based study. J Hematol Oncol. 2024;17(1):99.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"684_CR40","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/sj.leu.2402152","volume":"15","author":"M van der Burg","year":"2001","unstructured":"van der Burg M, Barendregt BH, van Wering ER, Langerak AW, Szczepa\u0144ski T, van Dongen JJ. The presence of somatic mutations in Immunoglobulin genes of B cell acute lymphoblastic leukemia (ALL-L3) supports assignment as Burkitt\u2019s leukemia-lymphoma rather than B-lineage ALL. Leukemia. 2001;15(7):1141\u20133.","journal-title":"Leukemia"},{"issue":"3","key":"684_CR41","first-page":"83","volume":"102","author":"E Sabattini","year":"2010","unstructured":"Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of Haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83\u20137.","journal-title":"Pathologica"},{"issue":"20","key":"684_CR42","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood-2016-03-657379","volume":"127","author":"M Cazzola","year":"2016","unstructured":"Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood. 2016;127(20):2361\u20134.","journal-title":"Blood"},{"key":"684_CR43","doi-asserted-by":"publisher","first-page":"102758","DOI":"10.1016\/j.eclinm.2024.102758","volume":"75","author":"X-Y Li","year":"2024","unstructured":"Li X-Y, Kong X-M, Yang C-H, Cheng Z-F, Lv J-J, Guo H, et al. Global, regional, and National burden of ischemic stroke, 1990\u20132021: an analysis of data from the global burden of disease study 2021. EClinicalMedicine. 2024;75:102758.","journal-title":"EClinicalMedicine"},{"key":"684_CR44","doi-asserted-by":"publisher","first-page":"102613","DOI":"10.1016\/j.arr.2024.102613","volume":"104","author":"Q Liu","year":"2025","unstructured":"Liu Q, Wang H, Chen Z, Xiong J, Huang Y, Zhang S, et al. Global, regional, and National epidemiology of nasopharyngeal carcinoma in middle-aged and elderly patients from 1990 to 2021. Ageing Res Rev. 2025;104:102613.","journal-title":"Ageing Res Rev"},{"key":"684_CR45","doi-asserted-by":"publisher","first-page":"102873","DOI":"10.1016\/j.eclinm.2024.102873","volume":"77","author":"Z Bai","year":"2024","unstructured":"Bai Z, Han J, An J, Wang H, Du X, Yang Z, et al. The global, regional, and National patterns of change in the burden of congenital birth defects, 1990\u20132021: an analysis of the global burden of disease study 2021 and forecast to 2040. EClinicalMedicine. 2024;77:102873.","journal-title":"EClinicalMedicine"},{"key":"684_CR46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jare.2023.07.003","volume":"59","author":"B Wu","year":"2024","unstructured":"Wu B, Li Y, Shi B, Zhang X, Lai Y, Cui F, et al. Temporal trends of breast cancer burden in the Western Pacific region from 1990 to 2044: implications from the global burden of disease study 2019. J Adv Res. 2024;59:189\u201399.","journal-title":"J Adv Res"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00684-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00684-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00684-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:07:15Z","timestamp":1757254035000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00684-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00684-x","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}